Korean Market
EXCH
BUKWANG PHARMACEUTICAL IND
★

Bukwang Pharmaceutical Preliminary Q2 2026 Earnings: Sales Growth Continues, Profitability Deteriorates

 
EXCH
BUKWANG PHARMACEUTICAL IND
★

Bukwang Announces IR Conference Call for 2026 Q2 Earnings and R&D Update

 
EXCH
BUKWANG PHARMACEUTICAL IND
★

BUKWANG PHARMACEUTICAL Holds IR Meeting for Q1 2026 Earnings and R&D Update

 
EXCH
BUKWANG PHARMACEUTICAL IND
★

Latuda Adjunctive Therapy for MDD Phase 3 IND Approved, Expansion of Indication Expected

 
EXCH
BUKWANG PHARMACEUTICAL IND
★

BUKWANG Corporate Governance Report: Enhanced Shareholder Returns via Share Cancellation and Dividend Increase, Rights Offering and Acquisition for Growth

 
FTC
BUKWANG PHARMACEUTICAL IND
★

BUKWANG PHARMACEUTICAL, Routine OCI Group Status Disclosure... Stable Financial Structure, No Material Changes

 
EXCH
BUKWANG PHARMACEUTICAL IND
★

Acquisition of 74.97% Stake in Korea Union Pharmaceutical for 30 Billion Won via Third-Party Allotment

 
PERI
BUKWANG PHARMACEUTICAL IND
★

Bukwang Pharm 2026 Q1: Operating Profit Down but Dividend Maintained, R&D Pipeline Progressing

 
EXCH
BUKWANG PHARMACEUTICAL IND
★

Acquisition of Stake in Financially Weak Company

 
EXCH
BUKWANG PHARMACEUTICAL IND
★

IR Meeting for 2025 Q4 Results and R&D Progress